United States · 
Who invested in Grow Therapy?
Grow Therapy's investors include TCV, Growth Equity at Goldman Sachs Alternatives, Sequoia Capital, Goldman Sachs and Menlo Ventures, and 4 more on record. TCV led its latest round.
United States · Series D startup
Who invested in Grow Therapy
Funding summaryUpdated 26 Oct 2026
$150Mraised across 1 round since 2026, from 2 sources
- Latest round
- Series D, $150MMar 2026
- Led by
- TCV and Growth Equity at Goldman Sachs Alternatives
- Investors
- 9 (2 led)
The rounds
- Mar 2026Series D$150M
TCVLead- Growth Equity at Goldman Sachs AlternativesLead
Sequoia Capital
Goldman Sachs
Menlo Ventures
Village Global
SignalFire
Transformation Capital
BCi
Reported by AlleyWatch and 1 other
Everyone who backed them
Growth Equity at Goldman Sachs AlternativesGrowth equity1round, led 1
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
These 8 firms list Grow Therapy as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.
Quick answers about Grow Therapy
How much has Grow Therapy raised?
Grow Therapy has raised $150M across 1 round since 2026.
When did Grow Therapy last raise?
Grow Therapy's most recent round was a Series D of $150M in Mar 2026, led by TCV.
What was Grow Therapy's biggest round?
Its most recent round, $150M in Mar 2026, is also its largest on record.
Who backed Grow Therapy first?
Grow Therapy's first round on record, in Mar 2026, was backed by TCV, Growth Equity at Goldman Sachs Alternatives and Sequoia Capital and 6 others.
What stage is Grow Therapy at?
Grow Therapy's latest named round is a Series D, in Mar 2026.
Where is Grow Therapy based?
Grow Therapy is based in the United States.
Who led Grow Therapy's rounds?
TCV led the Series D in 2026.
Companies like Grow Therapy
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.